Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

  • End date
    Apr 1, 2026
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 11 May 2022
induction chemotherapy
chemotherapy regimen
intensity-modulated radiation therapy
nasopharyngeal carcinoma


To study the 2-year PFS (progression-free survival) of patients with stage II-III nasopharyngeal carcinoma treated with induction chemotherapy followed by two different doses of intensity modulated radiation therapy plus concurrent cisplatin chemotherapy


To explore the 2 year PFS of patients with stageII-III nasopharyngeal carcinoma treated with induction chemotherapy followed by reduced-dose radiotherapy and cisplatin versus standard dose radiotherapy plus cisplatin concurrent chemotherapy. The enrolled patients will receive 2 cycles of cisplatin-based induction chemotherapy, if radiographic CR/PR and EBV DNA=0 after induction chemotherapy, the patients will be randomised assigned to received 60 Gy IMRT combined with 3 cycles of cisplatin concurrent chemotherapy or 70Gy IMRT combined with 3 cycles of cisplatin concurrent chemotherapy.

Condition Nasopharyngeal Carcinoma
Treatment IMRT, induction chemotherapy, cisplatin concurrent chemotherapy
Clinical Study IdentifierNCT05304468
SponsorSun Yat-sen University
Last Modified on11 May 2022


Yes No Not Sure

Inclusion Criteria

Patients newly diagnosed with histologically confirmed non-keratinizing NPC (WHO type II or III)
Stage II-III(8thAJCC/UICC staging system)
Aged 18-70 years
ECOG = 0-1
HGB≥90 g/L,WBC≥4×109 /L,PLT≥100×109 /L
CCR≥60ml/min or Cr<1.5×ULN
CR/PR and EBVDNA undetectable after induction chemotherapy
Signed informed consent

Exclusion Criteria

WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma
Age <18 or >70years
Treatment with palliative intent
Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer
Pregnancy or lactation
History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume)
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes
Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), and emotional disturbance
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note